{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:53:42Z","timestamp":1782215622634,"version":"3.54.5"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>c-Myc is a pivotal oncogenic transcription factor in hepatocellular\ncarcinoma (HCC), driving tumor progression by regulating genes involved in proliferation,\nmetabolism, and cell survival. Although c-Myc represents an attractive therapeutic target,\nthe development of effective and safe small-molecule inhibitors remains challenging. The\npresent study aimed to evaluate the anticancer activity and underlying mechanism of a newly\nsynthesized c-Myc inhibitor, BP1, in hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>BP1 was synthesized as a novel small-molecule inhibitor targeting c-Myc. Its antitumor effects were investigated in Huh7 and HepG2 hepatocellular carcinoma cell lines.\nCell viability and clonogenic growth were assessed using MTT and colony formation assays,\nrespectively. Cell migration and invasion were examined by wound-healing and Transwell\nassays. Apoptosis was analyzed by Annexin V\/PI flow cytometry. The effects of BP1 on cMyc protein stability, downstream target gene expression, and glycolysis-related enzymes\nwere evaluated by Western blotting and quantitative PCR. In addition, the pharmacokinetic\nproperties of BP1 were characterized in vivo following single-dose administration using\nLC\u2013MS\/MS analysis and compartmental modeling<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>BP1 treatment markedly reduced cell viability, clonogenic capacity, migration, and\ninvasion in hepatocellular carcinoma cells, while significantly increasing apoptotic cell\ndeath. Mechanistic studies showed that BP1 decreased c-Myc protein stability without altering c-Myc mRNA levels, resulting in the suppression of c-Myc\u2013dependent transcriptional\nprograms and downregulation of key glycolytic enzymes. These changes were associated\nwith impaired cellular energy metabolism. Pharmacokinetic analysis revealed rapid systemic\nclearance and a relatively short plasma half-life of BP1, indicating a low likelihood of drug\naccumulation following administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The present findings indicate that BP1 exerts its antitumor effects primarily\nthrough post-transcriptional destabilization of c-Myc, rather than inhibition of c-Myc gene\nexpression. By disrupting c-Myc\u2013driven metabolic and proliferative signaling pathways,\nBP1 effectively suppresses multiple malignant phenotypes of hepatocellular carcinoma cells.\nThe observed pharmacokinetic profile further suggests that BP1 may offer advantages in\nterms of safety related to systemic exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>conclusion:<\/jats:title>\n                    <jats:p>BP1 exerts multi-faceted antitumor effects against HCC cells\u2014suppressing proliferation and motility, inducing apoptosis, and disrupting c-Myc\u2013driven metabolic programs. Combined with its rapid elimination profile, these findings support BP1 as a promising c-Myc\u2013targeted candidate for HCC and warrant further in vivo efficacy and safety studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>BP1 demonstrates potent anticancer activity against hepatocellular carcinoma\ncells by destabilizing c-Myc, inhibiting proliferation and motility, inducing apoptosis, and\ninterfering with c-Myc\u2013regulated metabolic pathways. In addition to its favorable pharmacokinetic properties, BP1 represents a promising lead compound for further preclinical development in hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115680096444603260224040327","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:23:36Z","timestamp":1782213816000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticancer Effect and Mechanism of Novel c-Myc Inhibitor BP1 on\nHepatocellular Carcinoma"],"prefix":"10.2174","volume":"26","author":[{"given":"Shengkun","family":"Cao","sequence":"first","affiliation":[{"name":"The Suqian Clinical College, Xuzhou Medical University, Xuzhou, China"},{"name":"Jiangsu Key Laboratory of New DrugResearch and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of New DrugResearch and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China"},{"name":"The Affiliated Suqian Hospital of XuzhouMedical University, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of New DrugResearch and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyun","family":"Ni","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of New DrugResearch and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7639-4753","authenticated-orcid":true,"given":"Qisi","family":"Lin","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of New DrugResearch and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680096444603260224040327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/255462\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115680096444603260224040327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:23:38Z","timestamp":1782213818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/255462\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115680096444603260224040327","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}